1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Affymax, Inc.

Affymax, Inc.

AFFY
Affymax, Inc.US flagOther OTC
0.00
USD
- -
- -
37,490.00Market Cap
Affymax, Inc.
AFFY
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
TTM
FRC
- -
0.39
0.82
0.5
0.23
7.78
2.97
5.44
6.09
4.59
1.43
2.6
0.04
- -
Revenue per Share
-43.22
-105.04
-103.13
-70.5
-101.76
-32.56
-2.88
-5.68
-4.06
-0.57
-1.84
-2.57
-0.39
0.07
Basic EPS, GAAP
- -
- -
- -
-65.85
-76.36
44.33
-3.28
-4.36
-4.32
-2.04
-2.2
-1.13
-1.8
-0.22
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-43.22
-143.41
- -
-285.78
-369.51
-111.89
-14.18
-19.6
-19.87
-15.88
-13.53
-14.96
-14.9
-14.73
Book Value per Share
-38.7
-139.63
- -
-285.78
-348.75
77.52
5.63
0.59
3.55
2.96
2.28
0.23
-0.04
0.14
Tangible Book Value per Share
- -
- -
- -
- -
- -
2
15
15
19
24
33
36
37
37
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
12
44
83
115
113
48
94
1
- -
Sales/Revenue/Turnover
- -
-27,519.42
100
-14,647.68
-45,958.11
-458.04
-110.83
-107.1
-68.71
-12.84
-128.68
-49.89
-2,776.99
-11,300
Operating Margin (%)
2
6
- -
1
1
1
1
1
2
2
2
2
1
- -
Depreciation Expense
-10
-28
-28
-21
-33
-48
-43
-87
-77
-14
-61
-93
-14
3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-27,229.13
-12,604.89
-14,170.86
-44,021.62
-411.8
-97.14
-104.42
-66.61
-12.51
-128.6
-98.98
-1,053.62
6,414.29
Profit Margin (%)
- -
- -
- -
23
53
228
139
34
57
52
87
3
-3
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-9
-37
- -
-87
-114
117
84
9
67
73
76
8
-1
5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-172.74
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.49
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'13
Mar'14
Jun'14
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
29
30
4

Working Capital

FRC

•

in mil. unless spec.
Dec'13
Mar'14
Jun'14
Total Current Assets
6
5
4
Cash, Cash Equivalents & STI
6
5
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
9
9
- -
Payables & Accruals
1
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
90.31%
-117.24%
Free Cash Flow
- -
10.04%
63.28%
Net Income, GAAP
37.65%
42.1%
-84.56%
Sales/Revenue/Turnover
1,600.53%
-4.35%
-98.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
63
3
14
15
94
2013
1
1
- -
- -
1
2014
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
0.88
-0.89
-0.68
-1.85
-2.57
2013
-0.72
0.41
-0.05
- -
-0.39
2014
-0.04
0.19
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
Similar Companies
Opiant Pharmaceuticals, Inc. (OPNT)
AlzeCure Pharma AB (ALZCUR.ST)
Dyadic International, Inc. (DYAI)
Theriva Biologics, Inc. (TOVX)
Ascentage Pharma Group International (6855.HK)
MedMira Inc. (MIR.V)
Business
Affymax, Inc. is a development-stage biopharmaceutical company primarily engaged in the development of novel peptide-based therapeutics for the treatment of serious and life-threatening conditions, particularly in the nephrology and specialty care sectors. Its core product historically included OMONTYS (peginesatide), designed to treat anemia due to chronic kidney disease in adult patients. The company focuses on peptide therapeutics intended to improve patient care by addressing unmet medical needs. Affymax operates mainly in the United States and is headquartered in New York, New York. Founded in 2001, the company had previously collaborated with Takeda Pharmaceutical Company on OMONTYS before the product's voluntary recall in 2013 due to safety concerns, leading to the termination of the partnership and withdrawal of the New Drug Application by Takeda in 2014. In recent years, Affymax has not maintained significant commercial operations or launched new products, undergoing strategic reviews and exploring alternatives following the termination of its collaboration with Takeda. The company currently does not report substantial ongoing drug development or revenue-generating activity. Its notable changes over the last 1-2 years include a lack of major product launches, partnerships, or acquisitions, reflecting a state of limited operational activity and no recent strategic expansions or new funding rounds reported publicly. Affymax remains listed on OTC markets under the ticker AFFY, with a minimal workforce and no current analyst coverage projecting future growth. The company's earlier strategic business segments involved biopharmaceutical research and development with a focus on innovation in nephrology-related therapeutics. Its target markets historically comprised healthcare providers and patients dealing with kidney disease and related anemic conditions. Despite its initial promise in peptide drug development, Affymax's present status is largely that of a minimal-operation entity without active marketed products or ongoing clinical programs as of late 2025. Overall, Affymax is a biopharmaceutical company with a concentration on peptide drug development, headquartered in New York, founded in 2001, with a legacy product OMONTYS that was recalled and collaboration ended, currently inactive in new therapeutic development or operational expansions.

Company News

APIChatGPT

  • defenseworld.net

    Financial Analysis: Affymax (OTCMKTS:AFFY) versus Arvinas (NASDAQ:ARVN)